Loading company…
Verge Analytics, Inc. (dba Verge Genomics) uses artificial intelligence to research drugs for neurodegenerative disorders.
Its lead candidate, VRG50635, a small-molecule PIKfyve inhibitor, has entered clinical trials for amyotrophic lateral sclerosis (ALS). Founded in 2015 and based in California, US, it is led by co-founder and CEO Alice Zhang. In July 2021 it raised USD 85 million in Series B funding from BlackRock, Eli Lilly & Company, Merck Global Health Innovation Fund and others, at a USD 214.93 million post-money valuation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in